RNAC – cartesian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cartesian Therapeutics (RNAC) had its "outperform" rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by BTIG Research.
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.
Cartesian Therapeutics (RNAC) was upgraded by Cantor Fitzgerald from "neutral" to "overweight". They now have a $16.00 price target on the stock.
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Form 4 Cartesian Therapeutics, For: Mar 13 Filed by: Singer Michael
Form SCHEDULE 13G Cartesian Therapeutics, Filed by: Squarepoint Ops LLC
Form 10-K Cartesian Therapeutics, For: Dec 31
Form 8-K Cartesian Therapeutics, For: Mar 09
Form SCHEDULE 13G/A Cartesian Therapeutics, Filed by: FMR LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.